MedTrace Logo

Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia

NCT07613138 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2026-05-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether tart cherry citrate effervescent tablets can lower uric acid levels in people with asymptomatic hyperuricemia (high uric acid levels without gout symptoms).

The main question it aims to answer is:

Does taking tart cherry citrate effervescent tablets lower uric acid levels more effectively than taking a placebo (inactive) tablet, when both groups also receive lifestyle guidance?

Researchers will compare two groups of participants. Both groups will receive lifestyle guidance (advice on diet and exercise). In addition:

* One group will take the tart cherry citrate effervescent tablets.
* The other group will take a placebo effervescent tablet (looks and tastes the same but contains no active ingredient).

The study will last 24 weeks.

Participants will:

* Take the assigned effervescent tablet twice daily for 24 weeks
* Follow lifestyle guidance for diet and exercise
* Attend scheduled clinic visits for checkups and tests
* Provide blood and urine samples for testing

Conditions

  • Hyperuricemia With or Without Gout

Interventions

DIETARY_SUPPLEMENT

tart cherry citrate effervescent table

Each effervescent tablet contains tart cherry extract and citrate. Participants take 4.0 g (one tablet) dissolved in 200-250 mL of water twice daily (morning and evening), regardless of meals. Daily total water intake is controlled at 2000-2500 mL. The tablet is taken as an adjunct to lifestyle guidance.

DIETARY_SUPPLEMENT

Placebo Control Group

Matching placebo effervescent tablet identical in appearance, taste, and preparation to the tart cherry citrate effervescent tablet but containing no active ingredients. Participants take 4.0 g (one tablet) dissolved in 200-250 mL of water twice daily (morning and evening), regardless of meals. Daily total water intake is controlled at 2000-2500 mL. The tablet is taken as an adjunct to lifestyle guidance.

Sponsors & Collaborators

  • Beijing Zhecheng Biotechnology Co., Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-25
Primary Completion
2027-12-31
Completion
2028-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07613138 on ClinicalTrials.gov